Log In Get Started
Insider Trading June 1, 2026 06:07 PM

Insider Activity and Analyst Upgrades Signal Positive Momentum for HealthEquity

Executive selling reported alongside strong quarterly earnings and increased price target from Citizens.

By Hana Yamamoto HQY

HealthEquity's Executive Vice President and General Counsel, Ladd Delano, sold shares of the company on May 28, 2026. Despite this planned insider sale, recent financial results for Q1 2027 demonstrated robust performance, including exceeding earnings per share (EPS) expectations. Furthermore, Citizens raised its price target for HealthEquity stock and improved future estimates, suggesting positive sentiment among market analysts.

Insider Activity and Analyst Upgrades Signal Positive Momentum for HealthEquity
HQY

Key Points

  • The company reported strong Q1 2027 results, with EPS of $1.24 beating expectations by 11.71%, and revenue reaching $354.6 million against a projected $351.87 million.
  • Analysts at Citizens increased the price target to $111 and improved estimates for fiscal years 2027 ($4.70 non-GAAP EPS) and 2028 ($5.46 non-GAAP EPS).
  • InvestingPro data indicates a high financial health score of 3.58/5 and suggests the stock may be undervalued at current market levels.

HealthEquity, Inc. (NASDAQ:HQY) recently saw activity involving executive insider transactions alongside highly favorable financial reporting and analyst revisions.

Ladd Delano, who serves as Executive Vice President and General Counsel at the company, conducted a sale of common stock on May 28, 2026. The transaction involved 7,500 shares of Healthequity's common stock, which were sold at $90 per share, resulting in a total proceeds of $675,000.

It is important to note that this sale was carried out under the framework of a Rule 10b5-1 trading plan. Mr. Delano had initially adopted this specific trading plan on June 12, 2025. Following the completion of this transaction, Ladd Delano's direct holdings in Healthequity common stock amount to 91,141 shares.

The company, HealthEquity, trades with a current market capitalization estimated at $7.36 billion and maintains a Price-to-Earnings (P/E) ratio of 34.5. External analysis from InvestingPro suggests that the stock may be undervalued based on its present levels. The financial health score provided by InvestingPro for the company is notably high, registering 3.58 out of a possible 5.

Adding to the recent activity, HealthEquity, Inc. reported strong financial outcomes for the first quarter of fiscal year 2027. These results surpassed what was anticipated by the market. Specifically, the company posted an earnings per share (EPS) of $1.24. This figure exceeded the projected estimate of $1.11 by a margin of 11.71%. In terms of revenue generation, HealthEquity reported $354.6 million, which was slightly above the market's projection of $351.87 million. These figures collectively underscore the company’s solid operational performance during this recent reporting period.

Market analysts have also responded positively to these developments. Citizens recently increased its price target for HealthEquity shares. The new price target was set at $111, representing an increase from a previous level of $110. Concurrently, the firm maintained a Market Outperform rating on the stock.

Furthermore, Citizens refined its forward-looking estimates: it raised the non-GAAP EPS estimate for fiscal 2027 to $4.70 (up from $4.59) and adjusted the corresponding estimate for fiscal 2028 up to $5.46 (from $5.32). The analyst also improved the assumption regarding the EBITDA margin for fiscal 2027 by 50 basis points, setting it at 44.6%. These multiple adjustments reflect a clear positive shift in analyst sentiment concerning HealthEquity’s overall financial trajectory and future outlook.

Key Points and Sector Impact: